Acumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trial

Acumen (ABOS) Pharmaceuticals presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Clinical Trials on Alzheimer’s Disease, CTAD conference. The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen’s Phase 1 INTERCEPT-AD trial, which did not use this approach. Furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid PET scans or lumbar puncture (LP) procedures among people who are not eligible to continue in screening. “The study is not only a testament to our commitment to advancing a next-generation treatment for Alzheimer’s disease but also our commitment to pioneering clinical trial designs that provide an improved patient experience,” said Daniel O’Connell, President and Chief Executive Officer of Acumen.